One of Europe’s largest venture capital firms is investing in life science companies through several funds which target seed, venture and growth-stage investments in European, North American and Asian companies. The initial investment size via these funds ranges from € 500K- € 10M and is in the form of straight equity. The firm is capable of leading or co-investing in financing rounds, however they prefer to have a local investor lead U.S. deals, unless it is a later-stage round (i.e. B, C, etc.) and the prior round was led by a U.S. investor. The firm has much more flexibility for European-based companies, and typically leads these rounds. The firm is aiming to make at least 6 more investments in 2016, with the average investment being € 3- € 5 M.
The firm takes a true venture approach to investing and prioritizes breakthrough technologies with a strong IP position. The firm is very interested in microbiome technologies and food technologies, and strongly believes in technologies at the intersection of food and pharma/biotech. Microbiome therapeutics and platforms are the primary interest, and the firm is willing to invest as early as pre-clinical in this subsector. As for other therapeutics preferred phase of development, typically only pre-clinical investments are made into companies with a platform technology, who aren’t relying on one therapeutic asset. Medical technology and connected health companies are also evaluated whatever the stage of development.
The firm prefers to work with mature, experienced management teams, but has no strict restrictions and is open to working with all entrepreneurs. The firm will invest in pre-revenue as well as revenue-generating companies, with maximum revenues of € 50M.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org